Press Release: Sarclisa® (isatuximab) plus KRd significantly improved rate of minimal residual disease negativity in transplant-eligible patients with newly diagnosed multiple myeloma versus KRd alone

https://ift.tt/WhUJOou

from Sanofi - Aventis Groupe https://ift.tt/eKjVlJE
via IFTTT